VistaGen Therapeutics receives Nasdaq deficiency notice for bid price Feb 6, 2026 04:14PM
VistaGen Therapeutics (VTGN) call put ratio 1 call to 1.1 puts as share price down 80% Dec 17, 2025 02:36PM
Jefferies Downgrades VistaGen Therapeutics (VTGN) to Hold Dec 17, 2025 02:21PM
Maxim Group Downgrades VistaGen Therapeutics (VTGN) to Hold Dec 17, 2025 12:20PM
William Blair Downgrades VistaGen Therapeutics (VTGN) to Market Perform Dec 17, 2025 12:01PM


Dec 17, 2025 10:40AM Stifel Downgrades VistaGen Therapeutics (VTGN) to Hold
Dec 17, 2025 09:35AM Lucid Capital Markets Downgrades VistaGen Therapeutics (VTGN) to Neutral
Nov 26, 2025 08:30AM Vistagen presents PH80 menopause research at medical meeting
Nov 25, 2025 10:54AM Increasing unusual call option volume: AMTM VTGN LEN FIP ROK RPD GNW ZM SMTC METU EAT ALHC
Nov 17, 2025 09:26AM Stifel Reiterates Buy Rating on VistaGen Therapeutics (VTGN)
Nov 14, 2025 12:23AM VistaGen Therapeutics (VTGN) reported Q2 revenue
Nov 4, 2025 04:53AM Increasing unusual call option volume: MET XLB KMB QURE VITL BBD ACVA AGL VTGN
Jun 25, 2025 08:36AM VistaGen Therapeutics (VTGN) names Elissa Cote Chief Corporate Development Officer
Jun 18, 2025 10:47AM Stifel Reiterates Buy Rating on VistaGen Therapeutics (VTGN)
Jun 2, 2025 08:31AM VistaGen Therapeutics (VTGN) on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial
Feb 5, 2025 08:32AM VistaGen Therapeutics (VTGN) Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Jan 14, 2025 08:33AM VistaGen Therapeutics (VTGN) Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
Nov 20, 2024 04:39PM Stifel Reiterates Buy Rating on VistaGen Therapeutics (VTGN)
Sep 23, 2024 08:31AM VistaGen Therapeutics (VTGN) Initiates PALISADE-4 Phase 3 Study of Fasedienol